Your browser doesn't support javascript.
loading
Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa.
Barry, Houreratou; Mutua, Gaudensia; Kibuuka, Hannah; Anywaine, Zacchaeus; Sirima, Sodiomon B; Meda, Nicolas; Anzala, Omu; Eholie, Serge; Bétard, Christine; Richert, Laura; Lacabaratz, Christine; McElrath, M Juliana; De Rosa, Stephen; Cohen, Kristen W; Shukarev, Georgi; Robinson, Cynthia; Gaddah, Auguste; Heerwegh, Dirk; Bockstal, Viki; Luhn, Kerstin; Leyssen, Maarten; Douoguih, Macaya; Thiébaut, Rodolphe.
Afiliação
  • Barry H; Centre MURAZ, Bobo-Dioulasso, Burkina Faso.
  • Mutua G; KAVI-Institute of Clinical Research University of Nairobi, Nairobi, Kenya.
  • Kibuuka H; Makerere University-Walter Reed Project, Kampala, Uganda.
  • Anywaine Z; Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe, Uganda.
  • Sirima SB; Centre National de Recherche et de Formation sur le Paludisme (CNRFP), Unité de Recherche Clinique de Banfora, Ouagadougou, Burkina Faso.
  • Meda N; Centre MURAZ, Bobo-Dioulasso, Burkina Faso.
  • Anzala O; KAVI-Institute of Clinical Research University of Nairobi, Nairobi, Kenya.
  • Eholie S; Unit of Infectious and Tropical Diseases, BPV3, Treichville University Teaching Hospital, Abidjan, Côte d'Ivoire.
  • Bétard C; Univ. Bordeaux, Inserm, Bordeaux Population Health Research Center, UMR 1219; Inria SISTM team; CHU Bordeaux; CIC 1401, EUCLID/F-CRIN Clinical Trials Platform, F-33000, Bordeaux, France.
  • Richert L; Univ. Bordeaux, Inserm, Bordeaux Population Health Research Center, UMR 1219; Inria SISTM team; CHU Bordeaux; CIC 1401, EUCLID/F-CRIN Clinical Trials Platform, F-33000, Bordeaux, France.
  • Lacabaratz C; Vaccine Research Institute (VRI), Créteil, France.
  • McElrath MJ; Vaccine Research Institute (VRI), Créteil, France.
  • De Rosa S; Université Paris-Est Créteil, Faculté de Médecine, INSERM U955, Team 16, Créteil, France.
  • Cohen KW; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
  • Shukarev G; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
  • Robinson C; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
  • Gaddah A; Janssen Vaccines and Prevention, Leiden, the Netherlands.
  • Heerwegh D; Janssen Vaccines and Prevention, Leiden, the Netherlands.
  • Bockstal V; Janssen Research & Development, Beerse, Belgium.
  • Luhn K; Janssen Research & Development, Beerse, Belgium.
  • Leyssen M; Janssen Vaccines and Prevention, Leiden, the Netherlands.
  • Douoguih M; Janssen Vaccines and Prevention, Leiden, the Netherlands.
  • Thiébaut R; Janssen Vaccines and Prevention, Leiden, the Netherlands.
PLoS Med ; 18(10): e1003813, 2021 10.
Article em En | MEDLINE | ID: mdl-34714820
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Infecções por HIV / Vacinação / Vacinas contra Ebola Tipo de estudo: Clinical_trials / Guideline Limite: Adult / Female / Humans / Male Idioma: En Revista: PLoS Med Assunto da revista: MEDICINA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Burquina Fasso
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Infecções por HIV / Vacinação / Vacinas contra Ebola Tipo de estudo: Clinical_trials / Guideline Limite: Adult / Female / Humans / Male Idioma: En Revista: PLoS Med Assunto da revista: MEDICINA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Burquina Fasso